p19Arf represses platelet-derived growth factor receptor β by transcriptional and posttranscriptional mechanisms

Molecular and Cellular Biology

Volumn 32, Issue 21, 2012, Pages 4270-4282

  Widau, Ryan C ^a   Zheng, Yanbin ^a,b   Sung, Caroline Y ^a,b   Zelivianskaia, Anna ^a   Roach, Lauren E ^a   Bachmeyer, Karen M ^a   Abramova, Tatiana ^a   Desgardin, Aurelie ^a   Rosner, Andrew ^a   Cunningham, John M ^a   Skapek, Stephen X ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; CCAAT BINDING FACTOR; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN P19; PROTEIN P53; RNA POLYMERASE II; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; ADP RIBOSYLATION FACTOR RELATED PROTEINS; ADP-RIBOSYLATION FACTOR RELATED PROTEINS; CDKN2A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MDM2 PROTEIN, MOUSE; MEMBRANE PROTEIN; PROTEIN MDM2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARF GENE; ARTICLE; CELL CULTURE; CELL HYPERPLASIA; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO DEVELOPMENT; EYE DEVELOPMENT; FEMALE; FIBROBLAST; GENE REPRESSION; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN SYNTHESIS; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; TUMOR SUPPRESSOR GENE; ANIMAL; C57BL MOUSE; CELL LINE; CYTOLOGY; EYE; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PHYSIOLOGY; PRENATAL DEVELOPMENT; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; VASCULARIZATION;

ADP-RIBOSYLATION FACTORS; ANIMALS; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EYE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PERICYTES; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RNA POLYMERASE II; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84868683808     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06424-11     Document Type: Article

References (67)

1. Ballagi AE, Ishizaki A, Nehlin JO, Funa K. 1995. Isolation and charac- terization of the mouse PDGF beta-receptor promoter. Biochem. Bio- phys. Res. Commun. 210:165-173.
2. Barrett TB, Seifert RA, Bowen-Pope DF. 1996. Regulation of platelet- derived growth factor receptor expression by cell context overrides regu- lation by cytokines. J. Cell Physiol. 169:126-138.
3. Clarke AR, et al. 1992. Requirement for a functional Rb-1 gene in murine development. Nature 359:328-330.
4. Crouse NR, Dahiya S, Gutmann DH. 2011. Rethinking pediatric gliomas as developmental brain abnormalities. Curr. Top. Dev. Biol. 94:283-308. 5. de Stanchina E, et al. 1998. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12:2434-2442.
5. de Stanchina E, et al. 1998. E1A signaling to p53 involves the p19(ARF) tumor suppressor.Genes Dev. 12:2434-2442.
6. Dickins RA, et al. 2005. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37:1289-1295.
7. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. 1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc- induced lymphomagenesis. Genes Dev. 13:2658-2669.
8. Freeman-Anderson NE, et al. 2009. Expression of the Arf tumor suppres- sor gene is controlled by TgfUniversal-GreekwithMathPi.-1.H92522 during development. Development 136: 2081-2089.
9. Gibson SL, et al. 2003. Inhibition of colon tumor progression and angio- genesis by the Ink4a/Arf locus. Cancer Res. 63:742-746.
10. Goldberg MF. 1997. Persistent fetal vasculature (PFV): an integrated in- terpretation of signs and symptoms associated with persistent hyperplastic primary vitreous (PHPV). Am. J. Ophthalmol. 124:587-626.
11. Goodrich DW, Wang NP, Qian Y, Lee EYHP, Lee WH. 1991. The retinoblastoma gene product regulates progression through G1 phase of the cell cycle. Cell 67:293-302.
12. Gromley A, Churchman ML, Zindy F, Sherr CJ. 2009. Transient expres- sion of the Arf tumor suppressor during male germ cell and eye develop- ment in Arf-Cre reporter mice. Proc. Natl. Acad. Sci. U.S.A. 106:6285- 6290.
13. Hackzell A, Uramoto H, Izumi H, Kohno K, Funa K. 2002. p73 inde- pendent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y. J. Biol. Chem. 277:39769- 39776.
14. Haddad R, Font RL, Reeser F. 1978. Persistent hyperplastic primary vitreous. A clinicopathologic study of 62 cases and review of the literature. Surv. Ophthalmol. 23:123-134.
15. Hede SM, et al. 2009. GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null back- ground. Glia 57:1143-1153.
16. Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C. 1999. Role of PDGF-B and PDGFR in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126:3047-3055.
17. Hernando E, et al. 2004. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430:797- 802.
18. Hesselager G, Uhrbom L, Westermark B, Nister M. 2003. Complemen- tary effects of platelet-derived growth factor autocrine stimulation and p53 or Ink4a-Arf deletion in a mouse glioma model. Cancer Res. 63:4305- 4309.
19. Hoch RV, Soriano P. 2003. Roles of PDGF in animal development. Development 130:4769-4784.
20. Ikeda S, et al. 1999. Severe ocular abnormalities in C57BL/6 but not in 129/Sv p53-deficient mice. Invest. Ophthalmol. Vis. Sci. 40:1874-1878.
21. Ito M, Yoshioka M. 1999. Regression of the hyaloid vessels and pupillary membrane of the mouse. Anat. Embryol. 200:403-411.
22. Izumi H, et al. 2001. Mechanism for the transcriptional repression by c-Myc on PDGF beta-receptor. J. Cell Sci. 114:1533-1544.
23. Jacks T, et al. 1992. Effects of an Rb mutation in the mouse. Nature 359:295-300.
24. Jacks T, et al. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1-7.
25. Jain RK, Booth MF. 2003. What brings pericytes to tumor vessels? J. Clin. Invest. 112:1134-1136.
26. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ. 1999. Tumor spectrum in ARF-deficient mice. Cancer Res. 59:2217-2222.
27. Kamijo T, et al. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. U.S.A. 95:8292-8297.
28. Kamijo T, et al. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649- 659.
29. Kelly-Spratt KS, Gurley KE, Yasui Y, Kemp CJ. 2004. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. PLoS Biol. 2:E242. doi: 10.1371/journal.pbio.0020242.
30. Kuo ML, et al. 2003. Arf induces p53-dependent and -independent anti- proliferative genes. Cancer Res. 63:1046-1053.
31. Lee EY, et al. 1992. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359:288-294.
32. Liu H, Dibling B, Spike B, Dirlam A, Macleod K. 2004. New roles for the RB tumor suppressor protein. Curr. Opin. Genet. Dev. 14:55-64.
33. Lujambio A, Lowe SW. 2012. The microcosmos of cancer. Nature 482: 347-355.
34. Macleod KF. 2008. The role of the RB tumour suppressor pathway in oxidative stress responses in the haematopoietic system. Nat. Rev. Cancer 8:769-781.
35. Mao DYL, et al. 2004. Promoter-binding and repression of PDGFRB by c-Myc are separable activities. Nucleic Acids Res. 32:3462-3468.
36. Martin AC, et al. 2004. Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the arf tumor suppressor gene. Invest. Ophthal- mol. Vis. Sci. 45:3387-3396.
37. McKeller RN, et al. 2002. The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc. Natl. Acad. Sci. U.S.A. 99:3848-3853.
38. Micalizzi DS, Ford HL. 2009. Epithelial-mesenchymal transition in de- velopment and cancer. Future Oncol. 5:1129-1143.
39. Nakamura H, et al. 2011. Cooperative role of the RNA-binding proteins Hzf and HuR in p53 activation. Mol. Cell. Biol. 31:1997-2009.
40. Oster SK, et al. 2000. Myc is an essential negative regulator of platelet- derived growth factor beta receptor expression. Mol. Cell. Biol. 20:6768- 6778.
41. Palmero I, Pantoja C, Serrano M. 1998. p19ARF links the tumour sup- pressor p53 to Ras. Nature 395:125-126.
42. Pomerantz J, et al. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
43. Qi Y, et al. 2004. p19Arf directly and differentially controls the functions of c-Myc independently of p53. Nature 431:712-717.
44. Qin XQ, Chittenden T, Livingston D, Kaelin WG. 1992. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 6:953-964.
45. Reichel MB, et al. 1998. High frequency of persistent hyperplastic pri- mary vitreous and cataracts in p53-deficient mice. Cell Death Differ. 5:156-162.
46. Rocha S, Campbell KJ, Perkins ND. 2003. p53- and Mdm2-independent repression of NF-Universal-GreekwithMathPi.-1.H9260B transactivation by the ARF tumor suppressor. Mol. Cell 12:15-25.
47. Saab R, Spunt SL, Skapek SX. 2011. Myogenesis and rhabdomyosarcoma the Jekyll and Hyde of skeletal muscle. Curr. Top. Dev. Biol. 94:197-234
48. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. 2003. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re- entry. Nature 424:223-228.
49. Sherr CJ. 1998. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:2984-2991.
50. Sherr CJ, DePinho RA. 2000. Cellular senescence: mitotic clock or culture shock? Cell 102:407-410.
51. Silva RL, et al. 2005. Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing mouse eye. EMBO J. 24:2803-2814
52. Skapek SX, Pan YR, Lee EY. 2006. Regulation of cell lineage specification by theretinoblastoma tumor suppressor. Oncogene 25:5268-5276.
53. Sorkin A, Westermark B, Heldin CH, Claesson-Welsh L. 1991. Effect of receptor kinase inactivation on the rate of internalization and degradation of PDGF and the PDGF beta-receptor. J. Cell Biol. 112:469-478.
54. Sugimoto M, Kuo ML, Roussel MF, Sherr CJ. 2003. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol. Cell 11:415-424.
55. Thornton JD, et al. 2007. Persistent hyperplastic primary vitreous due to somatic mosaic deletion of the Arf tumor suppressor. Invest. Ophthalmol. Vis. Sci. 48:491-499.
56. Ulanet DB, Hanahan D. 2010. Loss of p19(Arf) facilitates the angiogenic switch and tumor initiation in a multi-stage cancer model via p53- dependent and independent mechanisms. PLoS One 5:e12454. doi: 10.1371/journal.pone.0012454.
57. Uramoto H, et al. 2004. pRB, Myc and p53 are critically involved in SV40 large T antigen repression of PDGF b-receptor transcription. J. Cell Sci. 117:3855-3865.
58. Vaziri C, Faller DV. 1996. Down-regulation of platelet-derived growth factor receptor expression during terminal differentiation of 3T3-L1 pre- adipocyte fibroblasts. J. Biol. Chem. 271:13642-13648.
59. Vaziri C, Faller DV. 1995. Repression of platelet-derived growth factor beta-receptor expression by mitogenic growth factors and transforming oncogenes in murine 3T3 fibroblasts. Mol. Cell. Biol. 15:1244-1253.
60. Wang JL, Nister M, Bongcam-Rudloff E, Ponten J, Westermark B. 1996. Suppression of platelet-derived growth factor alpha- and beta-receptor mRNA levels in human fibroblasts by SV40 T/t antigen. J. Cell Physiol. 166:12-21.
61. Weber JD, et al. 2000. p53-independent functions of the p19Arf tumor suppressor. Genes Dev. 14:2358-2365.
62. Wu L, et al. 2003. Extra-embryonic function of Rb is essential for embry- onic development and viability. Nature 421:942-947.
63. Yang W, Wetterskog D, Matsumoto Y, Funa K. 2008. Kinetics of re-pression by modified p53 on the PDGF beta-receptor promoter. Int. J. Cancer 123:2020-2030.
64. Zhang Y, Xiong Y, Yarbrough WG. 1998. ARF promotes MDM2 degra- dation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734.
65. Zheng Y, et al. 2010. Tgfbeta signaling directly induces Arf promoter remodeling by a mechanism involving Smads 2/3 and p38 MAPK. J. Biol. Chem. 285:35654-35664.
66. Zindy F, et al. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:2424-2433.
67. Zindy F, et al. 2003. Arf tumor suppressor promoter monitors latent onco- genic signals in vivo. Proc. Natl. Acad. Sci. U.S.A. 100:15930-15935.